The revenue for Roducitabine is expected to reach an annual total of $16 mn by 2036 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Roducitabine Overview

Roducitabine is under development for the treatment of solid tumors such as refractory metastatic pancreatic cancer (third-line therapy), biliary cancer and non-small cell lung cancer. The drug candidate is administered through oral route. The drug candidate is a cytidine analog. It is a small molecule (fluorocyclopentenylcytosine), a prodrug, next-generation nucleoside compound. It acts by targeting DNA, RNA, and DNA methyltransferase 1. It was also under development for colorectal cancer, muscle-invasive bladder cancer (MIBC), small cell lung cancer, colon cancer, relapsed and renal cell carcinoma, ovarian cancer, advanced malignancies, metastatic bladder cancer resistant to gemcitabine and cervical cancer.

Processa Pharmaceuticals Overview

Processa Pharmaceuticals, formerly Heatwurx, is a biopharmaceutical company which develops and commercializes drugs for the treatment of skin diseases and various cancer types. It is investigating its lead product candidate: PCS499 to treat necrobiosis lipoidica (NL), a chronic, disfiguring skin disorder; and to treat the side effects of radiation in patients with head and neck cancer. The PCS499 holds Orphan Drug designation for the treatment of NL. The company is evaluating PCS100, an anti-fibrotic and anti-inflammatory drug against idiopathic pulmonary fibrosis (IPF) and primary glomerulonephritis. It operates in the US. Processa Pharmaceuticals is headquartered in Baltimore, Maryland, the US.

The operating loss of the company was US$27.5 million in FY2022, compared to an operating loss of US$12 million in FY2021. The net loss of the company was US$27.4 million in FY2022, compared to a net loss of US$11.4 million in FY2021.

For a complete picture of Roducitabine’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 2 September 2023

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.

Smarter leaders trust GlobalData